Security Snapshot

PALISADE BIO, INC. - Common Stock (PALI) Institutional Ownership

CUSIP: 696389402

13F Institutional Holders and Ownership History from Q2 2024 to Q2 2026

Latest Period

Q2 2026

Institutions Reporting

29

Shares (Excl. Options)

16,746,104

Price

$2.09

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+12,306,244
Value change
+$25,719,957
Number of holders
29
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
173,946,000
SEC-reported price per share
$1.96
Insider filing price
$1.96
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • PALI - PALISADE BIO, INC. - Common Stock is tracked under CUSIP 696389402.
  • 29 institutions reported positions in Q2 2026.
  • 12 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 95 to 29 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from $261,721,164 to $34,969,120.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 29 institutions filings for Q2 2026.

Open SEC evidence

Security key

696389402

Latest holder period

Q2 2026

13F holders

29

13D/G owners

12

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
12
Security
PALI
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 9.9% 0% $30,835,838 +$3,278,888 17,620,479 +12% RA Capital Management, L.P. 31 Mar 2026
PERCEPTIVE ADVISORS LLC 10% 0% $29,184,225 +$5,677,630 15,200,117 +24% Perceptive Advisors LLC 31 Dec 2025
JANUS HENDERSON GROUP PLC 10% $27,835,737 14,885,421 JANUS HENDERSON GROUP PLC 28 Nov 2025
Commodore Capital LP 7.2% -27% $21,641,858 +$4,683,194 12,366,776 +28% Commodore Capital LP 31 Mar 2026
BlackRock, Inc. 6% $21,811,785 10,436,760 BlackRock, Inc. 30 Jun 2026
Octagon Capital Advisors LP 6.4% $18,370,364 9,567,898 Octagon Capital Advisors LP 31 Dec 2025
Soleus Capital Master Fund, L.P. 5.4% $18,239,690 9,353,687 Soleus Capital Master Fund, L.P. 26 May 2026
FRANKLIN RESOURCES INC 6% $21,358,511 9,163,990 Franklin Resources, Inc. 31 Dec 2025
AMERIPRISE FINANCIAL INC 5.3% $15,244,924 8,711,385 Ameriprise Financial, Inc. 31 Mar 2026
Squadron Capital Management LLC 3% -61% $8,640,000 -$7,200,000 4,500,000 -45% Squadron Master Fund LP 31 Dec 2025
ARMISTICE CAPITAL, LLC 10% 0% $335,053 +$132,407 471,906 +65% Armistice Capital, LLC 31 Mar 2025
Point72 Asset Management, L.P. 0.2% -97% $720,601 -$17,646,090 411,772 -96% Point72 Asset Management, L.P. 31 Mar 2026

As of 30 Jun 2026, 29 institutional investors reported holding 16,746,104 shares of PALISADE BIO, INC. - Common Stock (PALI). This represents 9.6% of the company’s total 173,946,000 outstanding shares.

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
9
Latest
Q2 2026
Rows shown
1-9 of 9
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q2 16,746,104 $34,969,120 +$25,719,957 $2.09 29
2026 Q1 149,487,450 $261,721,164 +$17,397,309 $1.75 95
2025 Q4 135,909,594 $319,442,849 +$306,785,730 $2.35 87
2025 Q3 119,592 $102,817 +$30,259 $0.86 12
2025 Q2 84,610 $57,544 -$119,036 $0.68 11
2025 Q1 260,593 $176,598 -$26,884 $0.68 11
2024 Q4 199,223 $328,718 +$210,668 $1.65 9
2024 Q3 62,098 $220,448 +$113,672 $3.55 8
2024 Q2 30,078 $135,352 +$135,352 $4.50 7
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .